24/7 Market News Snapshot 26 December, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

December 26, 2024

DENVER, Colo., 26 December, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) has made significant strides recently, reflecting a robust uptick in its stock price, which reached $0.826 in pre-market trading, showing a 4.96% increase from the prior close of $0.787. This surge is indicative of heightened investor interest, as demonstrated by a trading volume of 6.70 million shares. Analysts suggest that this momentum may be fueled by favorable news, and if the positive trend persists, the company could approach key resistance levels. Investors are advised to keep an eye on volume trends and wider market conditions to gauge potential future movements.

In addition to its encouraging market performance, Hoth Therapeutics has announced an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA) and Emory University aimed at combating obesity and related health conditions. The partnership provides Hoth with exclusive rights to a promising patent portfolio centered on “Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions.” This technology represents a significant advancement in the treatment of obesity, reinforcing Hoth’s commitment to developing innovative healthcare solutions.

Robb Knie, CEO of Hoth Therapeutics, expressed enthusiasm for the collaboration, noting that it signifies a pivotal step in introducing transformative therapies for obesity and enhancing patient care on a global scale. The agreement not only allows Hoth to develop, market, and commercialize products stemming from the patented technology but also includes a comprehensive development plan to facilitate progress from research to commercialization.

Moreover, Hoth is amplifying its intellectual property strategy with a recently signed Letter of Intent for additional provisional patent protection for HT-001, an innovative therapeutic aimed at various cancer treatment applications. This move aligns with Hoth’s objective of addressing unmet medical needs and broadening its therapeutic offerings in the healthcare landscape.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.